Identification of the Metabolic Enzyme Involved Morusin Metabolism and Characterization of Its Metabolites by Ultraperformance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (UPLC/Q-TOF-MS/MS)

Xianbao Shi,1 Brianna Mackie,1,2 Gang Zhang,2 Shuman Yang,3 Yonggui Song,4 Dan Su,4 Yali Liu,4 and Lina Shan1

1Department of Pharmacy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China
2Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA
3Department of Internal Medicine/Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada
4Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China

Correspondence should be addressed to Lina Shan; shanlina123@163.com

Received 12 May 2016; Revised 27 July 2016; Accepted 2 August 2016

Academic Editor: Con Stough

Copyright © 2016 Xianbao Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Morusin, the important active component of a traditional Chinese medicine, Morus alba L., has been shown to exhibit many vital pharmacological activities. In this study, six recombinant CYP450 supersomes and liver microsomes were used to perform metabolic studies. Chemical inhibition studies and screening assays with recombinant human cytochrome P450s were also used to characterize the CYP450 isoforms involved in morusin metabolism. The morusin metabolites identified varied greatly among different species. Eight metabolites of morusin were detected in the liver microsomes from pigs (PLMs), rats (RLMs), and monkeys (MLMs) and six metabolites were detected in the liver microsomes from humans (HLMs), rabbits (RAMs), and dogs (DLMs). Four metabolites (M1, M2, M5, and M7) were found in all species and hydroxylation was the major metabolic transformation. CYP1A2, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP2C19 contributed differently to the metabolism of morusin. Compared to other CYP450 isoforms, CYP3A4 played the most significant role in the metabolism of morusin in human liver microsomes. These results are significant to better understand the metabolic behaviors of morusin among various species.

1. Introduction

Flavonoids and their derivatives are important components of the human diet and exhibit many diverse pharmacological effects [1, 2]. Morusin (Figure 1) is a prenylated flavonoid that was first isolated from the root bark of Morus alba L. in 1978 and then later characterized in 2001 [3, 4]. In previous studies, we discovered that morusin exhibits strong inhibitory activity against primary UGTs and CYP450s. Additionally, our findings revealed significant differences in its metabolism between species and found that dog models are the optimum model to study morusin metabolism [5].

Like most flavonoids, morusin has antitumor [6, 7], anti-inflammatory [8], and antibacterial [9] activity. However, it is unclear if morusin or its metabolites produce these biological activities. Additionally, the side effects and toxic reactions of morusin may also be related to its metabolites. Therefore, determination of only the parent drug may not fully reflect its true pharmacologic and toxic nature. Identification of metabolites of a potential drug candidate plays an important role in drug development and can provide essential information on drug efficacy and its toxicological profile. Recently, metabolic studies have been performed in the early stages of drug discovery to determine whether the potential drug candidate is worth further development [10].

A simple and effective analytical method to reveal the structures of possible active constituents is a significant and valuable tool. Mass spectrometry coupled to liquid chromatography (LC-MS) [11, 12], mass spectrometry coupled to
gas chromatography (GC-MS) [13, 14], and nuclear magnetic resonance (NMR) [15, 16] are most frequently used to identify the structures of drugs. Compared to GC-MS or NMR, LC-MS based techniques are often used for metabolite identification due to their superior selectivity, sensitivity, and rapid rate of analysis [12].

In this study, the morusin metabolite profiling was performed through ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight/high-definition mass spectrometry (UPLC/ESI-Q-TOF/HDMS) combined with pattern recognition approaches and pathway analysis. The system has proven to have higher sensitivity than the traditional high-resolution MS system and has been used to identify many drug structures [17, 18]. In addition, CYP450 isoymes involved in the metabolism of morusin were also confirmed by assays with recombinant CYP450 isoforms and chemical inhibition experiments. Finally, molecular docking was employed to further understand the interactions between morusin and CYP450s.

2. Materials and Methods

2.1. Materials. Morusin was purchased from Shifeng Corp in Shanghai, China, and its purity was above 98%. Furafylline, xanthotoxin, quercetin, sulfaphenazole, omeprazole, quindine, clomethiazole, ketoconazole, glucose-6-phosphate dehydrogenase, NADP⁺, D-glucose-6-phosphate, 4-methylumbelliferone (4-MU), 4-methylumbelliferone-β-D-glucuronide (4-MUG), Tris-HCl, 7-hydroxycoumarin, and uridine 5‘-diphosphoglucuronic acid (UDPGA) (trisodium salt) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human supersomes (CYP1A2, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP2C19) were obtained from BD Gentest Corp. (Woburn, MA, USA). All other reagents were of HPLC grade or of the highest grade commercially available.

2.2. Preparation and Characterization of Liver Microsomes. Liver microsomes from humans (HLMs), monkeys (MLMs), rabbits (RLMs), rats (RLMs), dogs (DLMs), and minipigs (PLMs) were provided by the Research Institute for Liver Disease Co. (Shanghai, China). The HLMs were prepared from eleven individual human donor livers. MLMs, RAMs, RLMs, DLMs, and PLMs were prepared from ten individual animal livers. Protein concentration and microsome activities of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 had been previously characterized by the Research Institute for Liver Disease Co.

2.3. Analytical Instruments and Conditions. The HPLC conditions have been elaborated by us previously [5]. Briefly, HPLC system (Shimadzu, Kyoto, Japan) consisted of a CBM-20A lite system controller, two LC-20AB pumps, and an SPD-20A ultraviolet light (UV) detector. The chromatographic separation was performed on a C18 column (4.6 mm x 150 mm, 5 mm Kromasil). The mobile phases A and B comprised 0.1% formic acid in water and acetonitrile, respectively. The gradient profiles were as follows: 0–12 min, 55% B; 12–13 min, 55–90% B; 13–19 min, 90% B; 19–20 min, 90–55% B; 20–25 min, 55% B. The flow rate, column temperature, and wavelength were set as 1 mL/min, 40°C, and 270 nm, respectively.

LC-MS/MS analysis was performed on Ultra-Performance Liquid Chromatograph (UPLC) equipped with a Q-TOF SYNAPT G2-Si High Definition Mass Spectrometry (Waters Corporation, Milford, MA). Each sample (2 μL) was injected into a Welch C18 column (1.7 mm x 100 mm, 1.7 μm, Milford, USA) using an Acquity H-class UPLC system (Waters Corporation, USA). The column oven was maintained at 40°C. The mobile phase consisted of LC grade water with 0.1% formic acid (A) and LC grade acetonitrile (B) with the following gradient profile: 0–12 min, 55% B; 12–13 min, 55–90% B; 13–19 min, 90% B; 19–20 min, 90–55% B; 20–25 min, 55% B. The mass spectrometer was operated in negative mode and the mass range was set from 100 m/z to 500 m/z. Optimum parameters were as follows: ESI collision gas was Argon, trap collision energies were 6 V (low energy) and 20–50 V (high energy), the capillary and cone voltages were 2.2 kV and 40 V, the source and desolvation temperatures were 120 and 600°C, and the cone and desolvation gas flows were 50 and 800 L h⁻¹.

2.4. Incubation Systems with Liver Microsomes or Recombinant CYP450 Supersomes. The optimum incubation conditions of microsomes have been reported [5]. In brief, the typical incubation system contains 100 mM potassium phosphate buffer (pH 7.4), a NADPH-generating system (1 mM NADP⁺, 10 mM glucose-6-phosphate, 1 unit/mL of glucose-6-phosphate dehydrogenase, and 4 mM MgCl₂), the appropriate concentration of liver microsomes or recombinant CYP450s supersomes, the corresponding probe substrate, and morusin (or positive inhibitor for different probe reactions) in a final volume of 200 μL. According to preliminary experiments (data not shown), the final protein concentration of 0.3 mg/mL in liver microsomes or 15 nM in recombinant human supersomes and a 30 min reaction time were selected to ensure linear formation of metabolites during the incubations. There was a 3 min preincubation at 37°C before the reaction was initiated by adding the NADPH-generating system. The reaction was placed on ice and terminated by adding 200 μL acetonitrile and an internal standard. The mixture was centrifuged at 20,000 x g for 20 min and an
with each of the recombinant CYP450s (15 nM) at 37°C for 60 min and potential metabolites were monitored by HPLC.

2.5. Assay with Recombinant P450s. Six cDNA-expressed human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) were used to screen the involved isoform(s) for morusin metabolites. The incubations were carried out with each of the CYP450 isoforms using the protocol described above. Morusin (10 μM) was incubated with each of the recombinant CYP450s (15 nM) at 37°C for 60 min and potential metabolites were monitored by HPLC.

2.6. Chemical Inhibition Assays. In this study, morusin metabolism in HLMs was measured in the absence or presence of selective inhibitors for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 to explore the enzyme(s) involved in the biotransformation of morusin. The positive control inhibitors of individual CYP450 isoforms were as follows: furafylline (10 μM) for CYP1A2, xanthotoxol (2.5 μM) for CYP2A6, quercetin (2 μM) for CYP2C8, sulfaphenazole (10 μM) for CYP2C9, omeprazole (20 μM) for CYP2C19, quinidine (10 μM) for CYP2D6, clomethiazole (50 μM) for CYP2E1, and ketoconazole (1 μM) for CYP3A4.

2.7. Docking Studies of Morusin into the Reported Structures of CYP3A4. In order to further assess morusin metabolism by CYP3A4, molecular docking analysis with Gold v5.2 was implemented. This docking method has been reported previously [19]. The crystal structures of human CYP3A4 (pdb: 4K9W) were obtained from RCSB Protein Databank (http://rcsb.org/). SYBYL X2.1 was used for protein and ligand preparation, and energy minimization was completed through the external Tripos force field. The protonation state and energy minimization of the protein and the ligands were calculated using the default settings in SYBYL X2.1. The docked poses were scored using CHEMPLP scoring function. The highest scored docked pose of the ligand was visualized using Pymol Molecular Graphics System v1.3.

3. Results

3.1. Identifying CYP450s Involved in the Metabolism of Morusin. cDNA-expressed human P450 isoforms were used to investigate the enzymes involved in the formation of M1. Quantification of M1 in HLMs was normalized to 100% and other enzymes including CYP3A4, CYP2C19, CYP2D6, CYP2E1, CYP2C9, and CYP1A2 were compared with its counterpart from HLM incubation. As shown in Figure 2, the amount of M1 generated by CYP3A4, CYP2C19, CYP2D6, CYP2E1, CYP2C9, and CYP1A2 was 22.6%, 6.4%, 0.6%, 1.7%, 5.9%, and 2.1% of the amount incubated in HLMs, respectively. In addition, we also used chemical inhibition assays to confirm the key role of CYP450s in metabolizing morusin. The formation of M1 could be potently inhibited by ketoconazole (a potent inhibitor of CYP3A4) to less than 20% activity, while the selective inhibitors of other CYP450 isoforms had minor effects on the formation of M1 (Figure 3).

3.2. Structure Characterization of Metabolites by LC-MS/MS. In this study, the biotransformation of morusin was investigated by incubating morusin with different liver microsomes. Eight metabolites (M1–M8) were identified from MS and MS/MS data. All of the morusin metabolites were detected in PLMs, RLMs, and MLMs. Six metabolites were detected in HLMs (M1–M3, M5–M7), RAMs (M1–M3, M5, M7, and M8), and DLM (M1, M2, and M4–M7). Morusin metabolite data is listed in Table 1, and the structural skeleton of morusin and its potential metabolic pathways are shown in Figure 4. The parent compound, morusin, had a retention time of 9.17 min and was easily elucidated from the standard by comparison of retention time and MS data. Morusin (m/z 244) was monitored from the standard and morusin metabolites.
419.1545) exhibited eleven characteristic fragment ions at m/z values of 350, 349, 335, 321, 309, 297, 217, 201, 191, 147, and 121 (Figure 5(a)). Fragment ions at m/z 217.0561 and 201.0641 were produced by retro-Diels-Alder (RDA) cleavage and further fragmented to produce m/z 191.0776 and 147.0441. The fragment ion at m/z 191.0776 was produced from parent ion at m/z 217.0561 through losing a CO and adding two hydrogens at C-10. The fragment ion at m/z 335.0574 was a daughter ion of parent ion at 349.0852 by losing -CH₂.

M₁ and M₂ were isomers with the same molecular formula (C₂₅H₃₂O₅) but different MS/MS and retention times (7.15 and 8.66 min). They showed a m/z of 16 Da more than morusin indicating that the two metabolites were hydroxylated morusin occurring at C-5 and C-14, respectively. The cleaved pathways and fragment ions of M₁ and M₂ are shown in Figures 5(b) and 5(c). The product ion at m/z 351.0890 could be generated from a neutral loss (-C₆H₄OH) at C-3. The fragment ion at m/z 377 was a cyclization product from M₁ or M₂ occurring at C-14 and C-2'.

M₃ and M₄ had the same molecular formula of C₂₅H₂₂O₇ and showed a m/z of 2 Da less than M₁ or M₂. According to the cleaved pathways and fragment ions of M₃ and M₄ shown in Figures 5(d) and 5(e), they were identified as the cyclization and dehydrogenation products of M₁ and M₂, respectively.

The cyclized sites of M₃ or M₄ occurred at C-11 and C-2'.OH. M₅ underwent dehydration reaction and further produced the fragment ions at m/z 291, 361, and 401. Thus, M₅ was inferred to have a hydroxyl at C-5'. Because M₃ was produced from M₁, we inferred M₁ also had a hydroxyl at C-5'. M₅ and M₆ were also isomers with the same molecular formula of C₂₅H₂₆O₈ (m/z 453.1515) but different retention times. The ionized form of M₅ and M₆ was 34 Da more than the parent compound. According to the MS/MS spectra and information shown in Figures 5(f) and 5(g), M₅ and M₆ were identified as the reduction and dihydroxylation products of morusin. Exact mass determination and the corresponding chemical composition verify that M₅ was produced through the addition of two hydroxyl groups to the parent molecule at C-12 and C-5'. M₆ also has two more hydroxyl groups than morusin: one hydroxyl group was added in phenyl and the other hydroxyl group was added at C-12.

The molecular formula of M₇ was determined to be C₂₅H₂₆O₇ (m/z 437.1389) based on MS data and its ionized form was 18 Da more than the parent morusin. According to its molecular formula and MS/MS spectra, M₇ was identified as the hydration product of morusin where the hydroxyl group was bonded to C-12. Structural formula and fragmentation pathway of M₇ are shown in Figure 5(h).

Table 1: m/z of [M-H]⁻ measurements for the protonated molecules of metabolites in rat, monkey, pig, rabbit, human, and dog liver microsomes.

| Number | tᵣ  | Formula   | Mass     | Fragment | Error (ppm) | Metabolic reaction | Rats  | Monkey | Pigs | Rabbits | Human | Dog |
|--------|-----|-----------|----------|----------|-------------|-------------------|-------|--------|------|---------|-------|-----|
| M₀     | 9.17| C₂₅H₃₄O₆| 419.1545 | 350, 349, 335, 321, 309, 297, 217, 201, 191, 147, 121 | +1.1 | Parent | D   | D     | D    | D     | D     | D   |
| M₁     | 8.66| C₂₅H₃₂O₇| 435.1392 | 377, 325, 313, 285, 235, 217, 191, 121 | +0.2 | Hydroxylation | D   | D     | D    | D     | D     | D   |
| M₂     | 7.15| C₂₅H₃₂O₇| 435.1451 | 375, 351, 313, 285, 235, 217, 191 | −0.2 | Hydroxylation | D   | D     | D    | D     | D     | D   |
| M₃     | 7.50| C₂₅H₃₂O₇| 433.1195 | 401, 379, 361, 346, 291 | −0.1 | Hydroxylation + dehydrogenation | D   | D     | D    | D     | D     | ND  |
| M₄     | 7.09| C₂₅H₂₂O₇| 433.1285 | 401, 361 | +2.2 | Hydroxylation + dehydrogenation | D   | D     | ND   | ND    | ND    | D   |
| M₅     | 8.82| C₂₅H₂₆O₈| 453.1515 | 435, 350, 332, 325, 313, 309, 285, 235, 217, 191, 121 | +0.6 | 2 × hydroxylation + reduction | D  | D     | D    | D     | D     | D   |
| M₆     | 8.10| C₂₅H₂₂O₇| 453.1528 | 421, 393, 381, 350, 325, 313, 285, 235, 217, 191, 121 | −2.6 | 2 × hydroxylation + reduction | D  | D     | ND   | D     | D     | D   |
| M₇     | 8.34| C₂₅H₂₂O₇| 437.1389 | 419, 365, 339, 315, 297, 257, 219, 217, 191, 121 | +1.9 | Hydration | D   | D     | D    | D     | D     | D   |
| M₈     | 8.77| C₂₅H₂₂O₇| 451.1393 | 433, 419, 381, 375, 360, 333 | +0.2 | 2 × hydroxylation | D   | D     | D    | ND    | ND    | ND  |

D, detected; ND, not detected.
The ionized form of $M_8$ appeared at $m/z$ 451.1393 and was 32 Da more than morusin. Additionally, corresponding main fragment ions were found at $m/z$ 433.1366, 419.1509, 381.0969, and 375.0877. Therefore, $M_8$ was identified as a dihydroxylation product of morusin. According to the structures of fragment ions, the two new hydroxyl groups are potential bonded to C-14 and C-5′ (Figure 5(i)).

3.3. Analysis of Docking Results. CYP3A4 is the major enzyme involved in the metabolism of morusin. Therefore, we used molecular docking to study the molecular mechanism of interactions between morusin and CYP3A4. As shown in Figure 6, morusin binds to the active cavity of CYP3A4 through hydrogen bonding and $\pi-\pi$ stacking interactions. The hydrogen bonds occur with Arg106, MET371, Arg372, and Glu374, and $\pi-\pi$ stacking interactions occur with Phe108.

4. Discussion
Morusin has many significant properties including antitumor, antibacterial, and anti-inflammatory properties and its pharmacological effects have been studied thoroughly. However, the metabolic pathway and behavior of morusin in human and experimental animals vary greatly and have not been examined. In this study, a comparison of metabolic profiles, enzymes involved, and catalytic efficiency of morusin metabolism in liver microsomes from different species was performed.

It is necessary during a toxicity assessment to identify the enzyme(s) involved in morusin biotransformation in order to predict potential metabolite-drug interactions [20]. We identified CYP450 isoforms involved in morusin metabolism through screening assays with commercially available cDNA-expressed CYP450 isoforms including CYP1A2, CYP3A4,
Figure 5: Continued.
Figure 5: Continued.
Figure 5: Structural formula and fragmentation pathway of $M_6$–$M_8$. 
CYP2E1, CYP2C9, CYP2D6, and CYP2C19. Of the six CYP isoforms, CYP3A4 was identified as the enzyme most responsible for M₁ formation. Nevertheless, each of the six isoforms that catalyze the metabolism of morusin was weaker than when incubated in HLMs. This may be the reason that morusin displayed strong inhibition to CYP450s [5]. In addition, chemical inhibition studies were performed to confirm the CYP450 isoform that catalyzes morusin metabolism and the results indicated that the CYP3A4-specific inhibitor, ketoconazole, potently inhibited the formation of M₁. Therefore, these results verified that morusin is primarily catalyzed by CYP3A4 in comparison to other CYP450 isoforms. Molecular docking studies also confirmed that morusin binds in the active cavity of CYP3A4 and interacts through hydrogen bonds and π–π stacking. CYP3A4 has been identified as the important isozyme involved in the metabolism of many flavonoids such as nobiletin [21] and iripiflavone [22].

This study presents the fragmentation pathways of morusin through implementation of LC-MS/MS in negative ion mode and investigates its metabolites and metabolic pathways in six species. The results indicate that eight metabolites of morusin are primarily biotransformed through hydroxylation, reduction, cyclization, dehydrogenation, and dehydration reactions. Flavonoids with remarkable regioselectivity at the benzoannelated pyran ring are often formed through Retro Diels-Alder (RDA) reactions [23]. M₀, M₁, M₂, M₅, M₆, and M₇ were identified as the metabolites that underwent the RDA process. Under the effect of LC-MS/MS, M₃, M₄, or M₈ occurred dehydration reaction in phenyl and produced the corresponding fragment ions. Thus, we inferred that M₃, M₄, or M₈ had a hydroxyl at C-5’. Because M₄ was the dehydrogenation product of M₁, M₁ maybe has a hydroxyl at C-5’. All morusin metabolites were detected in PLMs, RLMs, and MLMs, which was consistent with previous publications which stated that pigs, rats, and monkeys have a greater capacity to metabolize morusin [5]. M₁, M₂, M₅, and M₇ were found in all species, which indicated that hydroxylation was the major metabolic transformation of morusin. This novel in vitro morusin metabolism information provided in our investigation is vital to develop a new drug and better understand the safety and efficacy of the drug.

In conclusion, eight metabolites from morusin were observed in the liver microsome incubation system and hydroxylation was the major metabolic transformation. CYP3A4 was the major isozyme involved in morusin metabolism, and molecular docking studies signified that morusin binds to CYP3A4 through hydrogen bonds and π–π interactions. Identification of the metabolites and metabolic enzymes for morusin is an important contribution to fully understand the pharmacological and toxicological profile of morusin its pharmacological and toxicological study.

Competing Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contributions
Xianbao Shi and Brianna Mackie contributed equally to this work.

Acknowledgments
The authors acknowledge the financial support from the Natural Science Foundation of Liaoning Province (Project no. 2014022005).

References
[1] A. Wojakowska, A. Piasecka, P. M. García-López et al., "Structural analysis and profiling of phenolic secondary metabolites of Mexican lupine species using LC-MS techniques," Phytochemistry, vol. 92, pp. 71–86, 2013.
[2] C. Li, A. Schmidt, E. Pichersky, F. Shi, and A. D. Jones, "Identification of methylated flavonoid regiosomeric metabolites using enzymatic semisynthesis and liquid chromatography-tandem mass spectrometry," Metabolomics, vol. 9, no. 1, pp. S92–S101, 2013.
[3] T. Nomura, T. Fukai, and M. Katayanagi, "Kuwanon A, B, C and oxydihydromorusin, four new flavones from the root bark of the cultivated mulberry tree (Morus alba L.)," Chemical and Pharmaceutical Bulletin, vol. 25, no. 3, pp. 529–532, 1977.
[4] Y.-S. Chi, H.-G. Jong, K.-H. Son, H.-W. Chang, S.-S. Kang, and H. P. Kim, "Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases," Biochemical Pharmacology, vol. 62, no. 9, pp. 1185–1191, 2001.
[5] X.-B. Shi, S.-M. Yang, G. Zhang et al., "The different metabolism of morusin in various species and its potent inhibition against UDP-glucuronosyltransferase (UGT) and cytochrome p450 (CYP450) enzymes," Xenobiotica, vol. 46, no. 5, pp. 467–476, 2016.
[6] C. Kim, J. H. Kim, E. Y. Oh et al., "Blockage of STAT3 signaling pathway by morusin induces apoptosis and inhibits invasion in human pancreatic tumor cells," Pancreas, vol. 45, no. 3, pp. 409–419, 2016.
B. Ding, Y. Lv, and Y.-Q. Zhang, "Anti-tumor effect of morusin from the branch bark of cultivated mulberry in Bel-7402 cells via the MAPK pathway," *RSC Advances*, vol. 6, no. 21, pp. 17396–17404, 2016.

H. J. Lee, J. Ryu, S. H. Park et al., "Effects of *Morus alba* L. and natural products including morusin on *In vivo* secretion and *In vitro* production of airway MUC5AC mucin," *Tuberculosis & Respiratory Diseases*, vol. 77, no. 2, pp. 65–72, 2014.

H.-Y. Sohn, K. H. Son, C.-S. Kwon, G.-S. Kwon, and S. S. Kang, "Antimicrobial and cytotoxic activity of 18 prenylated flavonoids isolated from medicinal plants: *Morus alba* L., *Morus mongolica* Schneider, *Broussonetia papyrifera* (L.) Vent, *Sophora flavescens* Ait and *Echinosophora koreensis* Nakai," *Phytomedicine*, vol. 11, no. 7-8, pp. 666–672, 2004.

H. Ouyang, M.-F. Zhou, Y.-C. Guo et al., "Metabolites profiling of *Pulsatilla* saponin D in rat by ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF-MS/MS)," *Fitoterapia*, vol. 96, pp. 152–158, 2014.

X. Zhang, D. I. Vernikovskaya, X.-M. Wang et al., "Quantitative determination of pravastatin and its metabolite 3alpha-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS," *Biomedical Chromatography*, vol. 30, no. 4, pp. 548–554, 2016.

A. L. Heffernan, K. Thompson, G. Eaglesham et al., "Rapid, automated online SPE-LC-QTRAP-MS/MS method for the simultaneous analysis of 14 phthalate metabolites and 5 bisphenol analogues in human urine," *Talanta*, vol. 151, pp. 224–233, 2016.

N. P. Vidal, M. I. Mananos, E. Goicoechea, and M. D. Guillén, "Farmed and wild sea bass (*Dicentrarchus labrax*) volatile metabolites: a comparative study by SPME-GC/MS," *Journal of the Science of Food and Agriculture*, vol. 96, no. 4, pp. 1181–1193, 2016.

M. Grapp, C. Sauer, C. Vidal, and D. Müller, "GC-MS analysis of the designer drug α-pyrrolidinovalerophenone and its metabolites in urine and blood in an acute poisoning case," *Forensic Science International*, vol. 259, pp. e14–e19, 2016.

B. Zhang, M.-Z. Xie, L. Bruschweiler-Li, K. Bingol, and R. Brischweiler, "Use of charged nanoparticles in NMR-Based metabolomics for spectral simplification and improved metabolite identification," *Analytical Chemistry*, vol. 87, no. 14, pp. 7211–7217, 2015.

Z.-X. Miao, M.-X. Jin, X. Liu et al., "The application of HPLC and microprobe NMR spectroscopy in the identification of metabolites in complex biological matrices," *Analytical and Bioanalytical Chemistry*, vol. 407, no. 12, pp. 3405–3416, 2015.

H. Chu, A.-H. Zhang, Y. Han et al., "Metabolomics approach to explore the effects of Kai-Xin-San on Alzheimer's disease using UPLC/ESI-Q-TOF mass spectrometry," *Journal of Chromatography B*, vol. 1015-1016, pp. 50–61, 2016.

S. Indelicato, D. Bongiorno, L. Ceraulo et al., "Electrospray ion mobility mass spectrometry of positively and negatively charged (1R,2S)-dodecyl(2-hydroxy-1-methyl-2-phenylethyl)dimethylammonium bromide aggregates," *Rapid Communications in Mass Spectrometry*, vol. 30, no. 1, pp. 230–238, 2016.

Z. Ma, X. Shi, G. Zhang, F. Guo, L. Shan, and J. Cai, "Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes," *Evidence-Based Complementary and Alternative Medicine*, vol. 2016, Article ID 5416509, 8 pages, 2016.

Y.-Y. Zhang, Y. Liu, J.-W. Zhang et al., "Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel," *Xenobiotica*, vol. 39, no. 4, pp. 283–292, 2009.

N. Koga, C. Ohta, Y. Kato et al., "*In vitro* metabolism of nobiletin, a polymethoxy-flavonooid, by human liver microsomes and cytochrome P450," *Xenobiotica*, vol. 41, no. 11, pp. 927–933, 2011.

Y. Moon, S.-Y. Kim, H.-Y. Ji et al., "Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes," *Xenobiotica*, vol. 37, no. 3, pp. 246–259, 2007.

K. Krohn, I. Ahmed, M. John, M. C. Letzel, and D. Kuck, "Stereo-selective synthesis of benzylated prodelphinidins and their diastereomers with use of the mitsunobu reaction in the preparation of their gallocatechin precursors," *European Journal of Organic Chemistry*, no. 13, pp. 2544–2554, 2010.